Title: Figure 1 from: Senapati S, Dash J, Sethi M, Chakraborty S (2020) Bioengineered probiotics to control SARS-CoV-2 infection. Research Ideas and Outcomes 6: e54802. https://doi.org/10.3897/rio.6.e54802
Type Image Senapati, Shantibhusan, Dash, Jayalaxmi, Sethi, Manisha, Chakraborty, Subhankar (2020): Figure 1 from: Senapati S, Dash J, Sethi M, Chakraborty S (2020) Bioengineered probiotics to control SARS-CoV-2 infection. Research Ideas and Outcomes 6: e54802. https://doi.org/10.3897/rio.6.e54802. Zenodo. Image. https://zenodo.org/record/3880867
Links
- Item record in Zenodo
- Digital object URL
Summary
Figure 1 Bioengineered probiotics to control SARS-CoV-2 infection. (a) Pathogenesis of SARS-CoV-2 depends on interaction between S protein of virus and angiotensin-converting enzyme 2 (ACE2) expressed on the surface of host cells. (b (1)) Engineered probiotics with expression of cell bound ACE2, sequesters the virus by making it bind to the ACE2 receptor on its surface thus inhibiting the viral entry into gut epithelial cells. (b (2)) The secreted form of ACE2 (sACE2) produced by probiotics confiscates the virus by binding to S proteins and masking their binding sites for gut epithelial ACE2. (c) The sACE2 could also have systemic effects due to its absorption into circulation and inhibiting the virus binding at distant organs like lungs.
More information
- URL: https://zenodo.org/record/3880867
- ISIDENTICALTO: https://doi.org/10.3897/rio.6.e54802.figure1
Subjects
- SARS-CoV-2, ACE2, probiotics
Dates
- Publication date: 2020
- Issued: June 06, 2020
Notes
Datacite resource type: FigureRights
- https://creativecommons.org/licenses/by/4.0/legalcode Creative Commons Attribution 4.0 International
- info:eu-repo/semantics/openAccess Open Access
Format
electronic resource
Relateditems
Description | Item type | Relationship | Uri |
---|---|---|---|
IsPartOf | https://doi.org/10.3897/rio.6.e54802 | ||
IsPartOf | https://zenodo.org/communities/covid-19 | ||
IsPartOf | https://zenodo.org/communities/zenodo |